Gyre Therapeutics Inc
GYRE
View Detailed Chart
7.880USD
+0.370+4.93%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
716.22MMarket Cap
105.86P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.93%
5 Days
-2.60%
1 Month
+7.87%
6 Months
+12.25%
Year to Date
+11.61%
1 Year
-34.88%
View Detailed Chart
TradingKey Stock Score of Gyre Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Gyre Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 81 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gyre Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Gyre Therapeutics Inc Highlights
StrengthsRisks
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 13219.52% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 105.86, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.16M shares, decreasing 11.35% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.28K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
18.000
Target Price
+139.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Gyre Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Gyre Therapeutics Inc Info
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Ticker SymbolGYRE
CompanyGyre Therapeutics Inc
CEOZhang (Ping)
Websitehttps://www.gyretx.com/
Related Instruments
+3.63%
+3.17%
+0.93%
+1.99%
+1.78%
+1.53%
-0.96%
+4.49%
+2.10%
+10.00%
+2.72%
+4.07%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69601.180
-368.950 (-0.53%)
282.580
+22.390 (+8.61%)
2102.820
+51.090 (+2.49%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
